Clinical Trial: Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07408258) titled 'Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors' on Feb. 06.

Brief Summary: ONC-783-001 is a Phase I open label, dose-escalation study for evaluating the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer.

Study Start Date: June 01, 2026

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumor

Intervention: DRUG: ONC-783

ONC-783 is a bispecific humanized monoclonal antibody targeting CD24 and CD3.

Recruitment Status: NOT_YET_RECRUITING

Sp...